Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load

AIDS

Volumn 28, Issue 14, 2014, Pages 2007-2021

  Kløverpris, Henrik N ^a,c,h   McGregor, Reuben ^a   McLaren, James E ^b   Ladell, Kristin ^b   Stryhn, Anette ^c   Koofhethile, Catherine ^a   Brener, Jacqui ^a   Chen, Fabian ^d   Riddell, Lynn ^e   Graziano, Luzzi ^f   Klenerman, Paul ^g   Leslie, Alasdair ^h   Buus, Søren ^c   Price, David A ^b,i   Goulder, Philip ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^e NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^f WYCOMBE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HIV; Human leukocyte antigen class I tetramers; Immune exhaustion; Programmed death 1 expression

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B15 ANTIGEN; HLA B42 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANTIGEN SPECIFICITY; ANTIGENIC VARIATION; ARTICLE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; LAG 3 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HIV; HIV INFECTIONS; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL;

EID: 84906934704     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000362     Document Type: Article

References (59)

1. + T-cell responses better define HIV disease progression than HLA genotype. J Virol 2010; 84: 4461-4468.
2. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity 2012; 37: 426-440.
3. + T cell efficacy in vaccination and disease. Nat Med 2008; 14: 623-628.
4. Saresella M, Rainone V, Al-Daghri NM, Clerici M, Trabattoni D. The PD-1/PD-L1 pathway in human pathology. Curr Mol Med 2012; 12: 259-267.
5. + T-cell memory and exhaustion. Immunol Rev 2010; 236: 167-175.
6. Youngblood B, Wherry EJ, Ahmed R. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr Opin HIV AIDS 2012; 7: 50-57.
7. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-499.
8. Utzschneider DT, Legat A, Fuertes Marraco SA, Carrie L, Luescher I, Speiser DE, et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 2013; 14: 603-610.
9. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
10. + T cells associated with reversible immune dysfunction. J Virol 2007; 81: 9249-9258.
11. + T lymphocytes in the liver. J Immunol 2007; 178: 2714-2720.
12. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138: 682-693.
13. Zhang Z, Zhang JY, Wherry EJ, Jin B, Xu B, Zou ZS, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 2008; 134: 1938-1949.
14. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
15. + T cell survival in HIV infection. J Exp Med 2006; 203: 2281-2292.
16. + T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-1202.
17. + T-cell exhaustion in typical progressors but not in long-Term nonprogressors. Blood 2007; 109: 4671-4678.
18. + T cells. PLoS Med 2008; 5: e100.
19. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206-210.
20. + T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2011; 16: 1147-1151.
21. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37.
22. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010; 107: 14733-14738.
23. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205: 2763-2779.
24. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011; 118: 965-974.
25. + T-cell exhaustion in HIV infection. Blood 2011; 117: 4805-4815.
26. Pacheco Y, McLean AP, Rohrbach J, Porichis F, Kaufmann DE, Kavanagh DG. Simultaneous TCR and CD244 signals induce dynamic downmodulation of CD244 on human antiviral T cells. J Immunol 2013; 191: 2072-2081.
27. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD, et al. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol 2012; 86: 5230-5243.
28. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13: 46-53.
29. Kloverpris HN, Harndahl M, Leslie AJ, Carlson JM, Ismail N, van Der Stok M, et al. HIV control through a single nucleotide on the HLA-B locus. J Virol 2012; 86: 11493-11500.
30. Matthews PC, Koyanagi M, Kloverpris HN, Harndahl M, Stryhn A, Akahoshi T, et al. Differential clade-specific HLA-BM3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. J Virol 2012; 86: 12643-12654.
31. Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol 2012; 13: 691-700.
32. + T-cell clonotypes by HIV. Blood 2011; 118: 2138-2149.
33. + T cells. J Virol 2010; 84: 10543-10557.
34. Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, Luzzi G, et al. HIV-1 infection is characterized by profound depletion of CD161R Th17 cells and gradual decline in regulatory T cells. AIDS 2010; 24: 491-502.
35. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigenspecific T lymphocytes. Science 1996; 274: 94-96.
36. Leisner C, Loeth N, Lamberth K, Justesen S, Sylvester-Hvid C, Schmidt EG, et al. One-pot, mix-And-read peptide-MHC tetramers. PLoS One 2008; 3: e1678.
37. Douek DC, Betts MR, Brenchley JM, Hill BJ, Ambrozak DR, Ngai KL, et al. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol 2002; 168: 3099-3104.
38. Janbazian L, Price DA, Canderan G, Filali-Mouhim A, Asher TE, Ambrozak DR, et al. Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J Immunol 2012; 188: 1156-1167.
39. + T cell populations specific for persistent DNA viruses. J Exp Med 2005; 202: 1349-1361.
40. Lefranc MP, Giudicelli V, Ginestoux C, Bodmer J, Muller W, Bontrop R, et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 1999; 27: 209-212.
41. + T-cell epitopes. J Virol 2007; 81: 3667-3672.
42. Rousseau CM, Birditt BA, McKay AR, Stoddard JN, Lee TC, McLaughlin S, et al. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods 2006; 136: 118-125.
43. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, et al. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol 2008; 82: 8548-8559.
44. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-Term-nonprogressing child. J Virol 2004; 78: 8927-8930.
45. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 2005; 201: 891-902.
46. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 2007; 21: 2005-2013.
47. Conrad JA, Ramalingam RK, Smith RM, Barnett L, Lorey SL, Wei J, et al. Dominant clonotypes within HIV-specific T cell responses are programmed death-1high and CD127low and display reduced variant cross-reactivity. J Immunol 2011; 186: 6871-6885.
48. + T cells in HIV infection. J Immunol 2009; 183: 1120-1132.
49. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15: 293-299.
50. + T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 2007; 110: 928-936.
51. Vollbrecht T, Brackmann H, Henrich N, Roeling J, Seybold U, Bogner JR, et al. Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection. J Med Virol 2010; 82: 358-370.
52. Vigano S, Bellutti Enders F, Miconnet I, Cellerai C, Savoye AL, Rozot V, et al. Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells. PLoS Pathog 2013; 9: e1003423.
53. + T-cell differentiation. J Virol 2013; 87: 1779-1788.
54. Petrovas C, Yamamoto T, Price DA, Rao SS, Klatt NR, Brenchley JM, et al. High production rates sustain in vivo levels of PD-1high simian immunodeficiency virus-specific CD8 T cells in the face of rapid clearance. J Virol 2013; 87: 9836-9844.
55. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204: 2473-2485.
56. + T-cell polyfunctionality and HIV-suppressive activity. Blood 2009; 113: 6351-6360.
57. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 1994; 180: 1283-1293.
58. Trautmann L, Mbitikon-Kobo FM, Goulet JP, Peretz Y, Shi Y, Van Grevenynghe J, et al. Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood 2012; 120: 3466-3477.
59. Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, et al. Cutting Edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol 2013; 191: 540-544.